REGENXBIO Inc. (RGNX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

REGENXBIO Inc. (RGNX) closed at USD 6.88 on 2026-10-14, a change of -47.7 % over the past year, with a market capitalization of USD 472.65M.

REGENXBIO Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

REGENXBIO Inc. key figures

Previous close

USD 6.88 (2026-10-14)

1-year change

-47.7 %

Market cap

USD 472.65M

Enterprise value

USD 617.6M

P/E ratio (trailing)

-1.93

P/E ratio (forward)

-2.41

EPS (trailing)

-3.72

EPS (forward)

-2.98

PEG ratio

n/a

Price to book

5.40

Revenue growth

405.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.07

Employees

371

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for REGENXBIO Inc. and compare it with other stocks.